Table 1

Baseline Characteristics

Post-MI CohortATH Cohort
Nonadherent
(n = 1,031)
Partially Adherent
(n = 1,263)
Fully Adherent
(n = 1,721)
Nonadherent
(n = 3,571)
Partially Adherent
(n = 4,941)
Fully Adherent
(n = 4,464)
Mean age, yrs56.6457.8056.2258.2059.7460.07
Male, %74.0176.7279.3171.0776.8379.32
Median household income in zip code, $64,33666,05866,82763,50467,84969,782
Race, %
 White§72.4574.5177.9873.2679.0283.90
 Black/African American§9.899.677.4611.898.045.79
Hispanic, %§7.106.575.626.534.992.93
Rural area, %37.5439.6736.0335.4234.6735.15
Suburban area, %27.5527.1628.1827.4727.7729.01
Urban area, %34.4332.6235.3936.8537.3835.66
Medicare, %15.1319.7914.1822.4028.3326.52
Total no. of prescriptions24.929.832.442.849.654.1
Mean ACE inhibitor copay per prescription during adherence period, $8.448.758.0511.1013.3413.68
Mean statin copay per prescription during adherence period, $24.9825.1523.4930.5535.6736.35
No. of primary care visits1.51.591.34.494.173.6
Diabetes, %34.0534.2025.6339.7939.1434.88
High cholesterol, %91.7694.6295.4199.24100.00100.00
Hypertension, %68.1977.1268.9792.0292.3189.65
Cerebrovascular disease, %5.927.215.6918.1517.3015.35
Chronic heart failure, %20.6620.4317.2620.6919.5917.38
Ischemic heart disease, %98.5599.5399.5486.5690.1091.78
Obesity, %4.465.784.655.665.085.20
Chronic renal failure, %4.175.863.784.904.513.43
COPD, %7.957.606.579.868.507.53
Atrial fibrillation, %8.448.236.228.269.218.94
Peripheral artery disease, %7.578.795.7515.3515.6513.93
Depression, %7.377.845.528.157.655.76
Charlson comorbidity score1.912.041.821.861.721.57

ACE = angiotensin-converting enzyme; ATH = atherosclerotic disease; COPD = chronic obstructive pulmonary disease.

  • Statistically significant difference, reference group: fully adherent (analysis of variance test).

  • Post–myocardial infarction (MI) statistically significant difference (chi-square test).

  • Atherosclerosis statistically significant difference (chi-square test). Statistically significant difference (p = 0.05).

  • § Percent likelihood.

  • 6-month adherence period for post-MI cohort, 1 year for ATH cohort.

  • 6-month pre-baseline period for post-MI cohort, 1 year for ATH cohort.